您现在的位置: 首页> 研究主题> 胰升糖素样肽1

胰升糖素样肽1

胰升糖素样肽1的相关文献在1996年到2021年内共计116篇,主要集中在内科学、药学、基础医学 等领域,其中期刊论文112篇、专利文献214927篇;相关期刊34种,包括国际老年医学杂志、中国病理生理杂志、临床内科杂志等; 胰升糖素样肽1的相关文献由292位作者贡献,包括洪天配、刘超、杨文英等。

胰升糖素样肽1—发文量

期刊论文>

论文:112 占比:0.05%

专利文献>

论文:214927 占比:99.95%

总计:215039篇

胰升糖素样肽1—发文趋势图

胰升糖素样肽1

-研究学者

  • 洪天配
  • 刘超
  • 杨文英
  • 刘亚辉
  • 刘烨
  • 刘翠萍
  • 史视明
  • 吴丽丽
  • 宁光
  • 易志刚
  • 期刊论文
  • 专利文献

搜索

排序:

年份

    • 马欢临; 易志刚
    • 摘要: 目的 研究胰升糖素样肽1(GLP-1)减轻高糖诱导的胎盘滋养细胞HTR8/SVneo炎症及凋亡的作用及分子机制.方法 收集妊娠期糖尿病(GDM)产妇及健康产妇的胎盘,检测miR-137及白细胞介素6(IL-6)的表达;培养胎盘滋养细胞HTR8/SVneo,分为低糖(5 mmol/L)处理的LG组、高糖(25mmol/L)处理的HG组、高糖联合GLP-1处理的GLP-1组、转染miR-137模拟物后高糖联合GLP-1处理的miR-137+GLP-1组、转染miR-137模拟物的miR-137模拟物组、转染阴性对照(NC)模拟物的NC模拟物组、转染miR-137抑制物的miR-137抑制物组、转染NC抑制物的NC抑制物组.测定细胞凋亡率、miR-137及IL-6的表达量.结果 HG组的细胞凋亡率及miR-137、IL-6的表达水平均明显高于LG组,GLP-1组的细胞凋亡率及miR-137、IL-6的表达水平均明显低于HG组,miR-137+GLP-1组的细胞凋亡率及miR-137、IL-6的表达水平均明显高于GLP-1组;miR-137模拟物组细胞的凋亡率及IL-6的表达水平均明显高于NC模拟物组,miR-137抑制物组细胞的凋亡率及IL-6的表达水平均明显低于NC抑制物组.结论 GLP-1通过抑制miR-137/IL-6途径减轻高糖诱导的胎盘滋养细胞HTR8/SVneo炎症及凋亡.
    • 杨毓莹
    • 摘要: 胰升糖素样肽1(GLP-1)的主要作用是抑制进食并促进葡萄糖刺激的胰岛素分泌.基础研究表明,生殖系统也是GLP-1的一个靶器官.由于GLP-1受体激动剂目前广泛用于管理肥胖症和2型糖尿病,因此有必要明确GLP-1对人体生殖系统的影响.J Clin Endocrinol Metab杂志发表了1篇《胰升糖素样肽1对健康男性生殖系统的影响》文章[Izzi-Engbeaya C,Jones S,Crustna Y,et al.Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men[J].J Clin Endocrinol Metab, 2020, 105(4).DOI: 10.1210/clinem/dgaa072],在获得原文刊发杂志授权同意后,本文为该文的中文编译.该文以随机、单盲、安慰剂对照设计,研究了急性GLP-1输注对健康男性性激素的影响.结果 显示,与安慰剂相比,血清促黄体生成素(LH)、卵泡刺激素(FSH)和睾酮的平均水平以及LH和睾酮的脉冲在GLP-1输注期间均无明显改变.该研究结果表明,急性GLP-1给药不会影响健康男性的性激素分泌.
    • 徐爱花; 毛皓愉; 何银辉; 徐海燕; 卢乐
    • 摘要: 目的 观察胰升糖素样肽1 (GLP-1)对血脂正常2型糖尿病患者冠脉病变的影响.方法 收集68例血脂正常2型糖尿病患者,按是否发生冠脉病变分为对照组和观察组,对照组为未发生冠脉病变患者共37例,观察组为发生冠脉病变患者共31例.比较两组一般资料、糖化血红蛋白(HbA1c)、脂蛋白a(LP-a)、血清胱抑素C(CysC)及GLP-1,并行多因素Logisitic回归分析.结果 两组HbA1c、LP-a、CysC及GLP-1水平差异均有统计学意义(均P< 0.05);HbA1c、LP-a、CysC及GLP-1是血脂正常2型糖尿病患者冠脉病变的危险因素(均P<0.05).结论 高HbA1c、高LP-a、高Cys C及GLP-1水平患者有冠脉病变的风险,临床上应该及早采取预防措施.
    • 丁立新
    • 摘要: 作为一类新型降糖药,胰升糖素样肽1受体激动剂的血压效应日益受到重视.在动物研究中,急、慢性用药却表现出不同的血压效应;临床系列研究已肯定这类药物慢性用药的降压作用,不同药物降压效果无明显差异.脑干神经核团、心脏、肾脏、血管内皮细胞等,可能与其影响血压的作用机制有关.本文对胰升糖素样肽1胰升糖素样肽1受体激动剂在动物和临床的血压效应及作用机制进行综述.
    • 郝明; 茅江峰; 聂敏; 于冰青; 高寅洁; 王曦; 伍学焱
    • 摘要: Mammalian reproduction is closely related to their metabolic status. The hypothalamus-pituitary-gonad axis ( HPG axis) is regulated by various metabolic factors. Glucagon-like peptide-1 ( GLP-1) is one of various metabolic factors that not only affect glycemic and metabolic control, but also with many other effects, including affecting HPA axis. The function of GLP-1 is related to the location of glucagon-like peptide-1 receptor ( GLP-1R) distribution. It has been confirmed that GLP-1R is widely distributed in HPG axis. The effects of GLP-1 and GLP-1R agonists on the HPG axis have also attracted much attention. The positive effects of GLP-1 and GLP-1R agonists on the HPG axis indicated it could be the new target for the new treatment for gonadal diseases. The role of GLP-1 and GLP-1R agonists in the central nervous system is reviewed.%哺乳动物的生殖能力与代谢状态密切相关,下丘脑-垂体-性腺轴(hypothalamus-pituitary-gonad axis,HPG轴)受多种代谢因子调控.胰升糖素样肽1(glucagon-like peptide-1,GLP-1)就是其中的一种,其不仅可以影响血糖和代谢状态,还可以直接作用于HPG轴.GLP-1功能与胰升糖素样肽1受体(glucagon-like peptide-1 receptor,GLP-1R)分布的位置有关,已有研究证实GLP-1R广泛分布于HPG轴.GLP-1及GLP-1R激动剂对于HPG轴的影响也引起了人们的关注,其对HPG轴的正向作用使之有望成为治疗性腺系统疾病的新手段.现将GLP-1、GLP-1R激动剂对HPG轴的作用进行综述.
    • 王力; 向光大; 郭孛; 张佳佳; 向林; 董靖; 刘敏
    • 摘要: 目的 探讨髓源性生长因子(MYDGF)对2型糖尿病小鼠胰升糖素样肽1(GLP-1)分泌的影响及机制.方法 通过给C57BL/6J野生型(WT)小鼠和MYDGF基因敲除(KO)小鼠注射链脲佐菌素建立2型糖尿病模型,分为糖尿病组(WT-D、KO-D)及非糖尿病组(WT-ND、KO-ND)检测相关指标.再根据是否予以腺相关病毒(AAV)-MYDGF干预,将小鼠分为野生型糖尿病对照组(WT-GFP)、野生型糖尿病MYDGF干预组(WT-MYDGF)、基因敲除型糖尿病对照组(KO-GFP)和基因敲除型糖尿病MYDGF干预组(KO-MYDGF),用野生型非糖尿病小鼠作为空白对照组,观察MYDGF对小鼠生化指标、GLP-1分泌及丝裂原活化蛋白激酶激酶(MEK)/细胞外信号调节蛋白激酶(ERK)信号通路的影响.结果 干预6周后,WT-ND和KO-ND组小鼠各糖脂代谢指标比较,差异无统计学意义(P>0.05),与WT-D组相比,KO-D组空腹血糖(FPG)、HbA1C及血脂水平升高,胰升糖素样肽原基因(gcg)、前蛋白转化酶3(pc3)mRNA表达降低,GLP-1分泌减少(均P0.05) . Compared with WT-D group, fasting plasma glucose (FPG), HbA1C, and blood lipid levels in KO-D group were increased, while gcg, pc3 mRNA, and GLP-1 secretion levels were decreased (all P<0.05). Compared with the WT-GFP group, FPG, HbA1C , and blood lipid levels were decreased in WT-MYDGF group, while gcg and pc3 mRNA, and GLP-1 secretion levels were increased (all P<0.05). KO group revealed a result similar to that in WT group after MYDGF intervention. Western blotting showed that the phosphorylation level of ERK1/2 was lowered in KO diabetic mice compared with WT diabetic mice, which was enhanced in WT and KO mice after MYDGF intervention. Conclusions MYDGF promotes the secretion of GLP-1 by activating MEK/ERK signaling pathway, thereby delaying the development of diabetes.
    • 曹磊; 赵英剑; 刘志敏; 王蕾; 周杨; 安亚伟; 陈雅静
    • 摘要: Objective To explore the correlation between the level of glucagon like peptide-1 (GLP-1) and the extent of coronary lesions in coronary heart disease (CHD).Methods One hundred and ninety-two CHD patients included in the study were divided into simple CHD group (n =60),CHD accompanied with impaired glucose tolerance(IGT) group (n =67),and CHD accompanied with type 2 diabetes mellitus (T2DM) group (n =65).48subjects were used as controls.The levels of GLP-1 in all the patients were analyzed by ELISA.Oral glucose tolerance test (OGTF) was performed.Blood glucose,insulin,and C-peptide levels were measured.The area under curves of insulin(AUCINS),C-peptide (AUCC-P),glucose (AUCGlu),and GLP-1 (AUCGLP-1) were calculated.All the patients underwent coronary angiography and the extent of coronary lesions was analyzed by total amount of coronary narrow degree integral.The association of GLP-1 level with coronary narrow degree was analyzed by correlation analysis and multivariate linear stepwise regression analysis.Results The levels of blood glucose and AUCGlu during OGTT in CHD accompanied with T2DM group were significantly higher than those in CHD with IGT group (P<0.01),while the levels of insulin and C-peptide,AUCINS,and AUCC-P were decreased (P<0.05).The levels of blood glucose,insulin,C-peptide,AUCGlu,AUCINs,and AUCC-P in CHD accompanied with IGT group were significantly higher than those in control group and simple CHD group (P<0.01).Compared with simple CHD group and CHD accompanied with IGT group,GLP-1 level in CHD accompanied with T2DM group was markedly decreased(P<0.01) while coronary artery narrow degree was raised(P< 0.05).Compared with simple CHD group,CHD accompanied with IGT group showed lower GLP-1 level and higher coronary artery narrow degree(P<0.01).Correlation analysis revealed that GLP-1 level was negatively correlated with the coronary artery narrow degree in CHD patients (P < 0.01).Multivariate linear regression analysis showed that systolic blood pressure,high density lipoprotein-cholesterol,fasting C-peptide and GLP-1 had a predictive effect on the coronary narrow degree integral in CHD patients.Conclusion The level of GLP-1 is closely correlated with the coronary artery narrow degree in CHD patients,especially in patients accompanied by hyperglycemia.%目的 探讨胰升糖素样肽1(GLP-1)水平与冠状动脉病变严重程度的关系.方法 收集192例冠心病患者,其中单纯冠心病组60例,冠心病合并糖耐量受损(IGT)组67例,冠心病合并2型糖尿病(T2DM)组65例,对照组48例,所有患者均采用酶联免疫吸附法测定GLP-1,进行口服葡萄糖耐量试验(OGTT),检测血糖、胰岛素、C肽,计算胰岛素曲线下面积(AUCINS)、C肽曲线下面积(AUCc-P)、血糖曲线下面积(AUCGlu)、GLP-1曲线下面积(AUCGLP-1),根据住院期间冠状动脉造影(CAG)结果,采用冠状动脉狭窄程度积分统计冠脉狭窄程度.采用相关分析和多元线性逐步回归分析,分析GLP-1水平与冠状动脉狭窄程度的关系.结果 冠心病合并T2DM组OGTT各时间点血糖及AUCGlu均较冠心病合并IGT组明显升高(P<0.01),胰岛素、C肽释放水平及AUCINS、AUCC-P明显降低(P<0.05).冠心病合并IGT组糖负荷后血糖、胰岛素、C肽水平及AUCGlu、AUCINS、AUCC-P均较对照组、单纯冠心病组明显升高(P<0.01).与单纯冠心病组及冠心病合并IGT组比较,冠心病合并T2DM组的GLP-1水平明显降低(P<0.01),冠脉狭窄程度积分升高(P<0.05);冠心病合并IGT组GLP-1水平较单纯冠心病组明显降低(P<0.01),冠脉狭窄程度积分升高(P<0.01).Pearson相关分析显示,GLP-1水平与冠脉病变积分呈负相关(P<0.01),多元线性相关分析显示,收缩压、高密度脂蛋白胆固醇、空腹C肽和GLP-1对冠心病患者冠脉狭窄程度评分有预测作用.结论 空腹GLP-1水平与冠心病患者的冠脉病变程度密切相关,尤其在合并血糖升高患者更为明显.
    • 摘要: 目的:研究胰升糖素样肽1受体激动剂利拉鲁肽对肥胖大鼠肝脏组织Sesn2/AMPK/mTOR信号通路的影响.方法:雄性SD大鼠随机分为正常饮食组(NC组)与高脂饮食组(HF组),喂养12周后,每组取5只评估肥胖大鼠模型建立.HF组再随机分为HF组、低剂量利拉鲁肽组(LG组)、中剂量利拉鲁肽组(MG组)与高剂量利拉鲁肽组(HG组),各组分别给予生理盐水及不同剂量利拉鲁肽(50、100和200μg/kg,皮下注射,每天2次)4周.16周时测定体重及附睾脂肪指数;取大鼠肝脏组织HE染色观察肝脏脂肪变性情况;Western blot法检测肝脏组织中Sesn2、AMPK、p-AMPK、mTOR和p-mTOR的蛋白水平.结果:HF组大鼠的体重明显高于NC组(P<0.01).HF组肝脏细胞出现脂肪变性.与NC组相比,HF组的Sesn2蛋白水平明显降低(P<0.01),p-AMPK/AMPK水平明显降低(P<0.01),而p-mTOR/mTOR水平与NC组相比差异没有统计学显著性.利拉鲁肽干预4周后,药物处理组大鼠体重明显低于HF组(P<0.01),MG与HG组大鼠的附睾脂肪指数较HF组降低(P<0.01),肝组织脂肪变性较HF组减轻;HG组的Sesn2蛋白水平明显高于HF组(P<0.01),MG与HG组的p-AMPK/AMPK水平较HF组明显升高(P<0.01),LG组、MG与HG组p-mTOR/mTOR水平较HF组明显降低(P<0.01).结论:胰升糖素样肽1受体激动剂可能通过Sesn2/AMPK/mTOR信号通路影响机体能量代谢,改善肥胖状态.
    • 洪天配; 田勍; 杨进
    • 摘要: The discovery and development of incretin effect has changed the landscape of diabetes treatment over past decades. Nowadays, incretin-based agents, such as glucagon-like peptide-1 ( GLP-1) receptor agonists and dipeptidyl peptidase-4 ( DPP-4) inhibitors have been wildly used in the therapy of type 2 diabetes. These agents show the beneficial effects on the multiple pathophysiological defects of type 2 diabetes, and provide a safe approach for achieving glycemic control with low risk of hypoglycemia and weight gain. Moreover, incretin-based therapies are still in development. Novel incretin-related therapies, such as fixed-dose combinations of GLP-1 receptor agonists and basal insulins, oral GLP-1 receptor agonists, and GLP-1 secretagogues, will be available in clinical practice in the near future.%肠促胰素效应的发现改变了糖尿病治疗格局.肠促胰素类降糖药物包括胰升糖素样肽1(GLP-1)受体激动剂和二肽基肽酶4(DPP-4)抑制剂,这类药物可纠正2型糖尿病的多重病理生理学缺陷,在有效改善血糖控制的同时,不会带来低血糖和体重增加的风险,故目前已广泛应用于临床实践.此外,以肠促胰素效应为靶点的药物研发仍处于不断探索进程中.与肠促胰素相关的新型治疗药物,如GLP-1受体激动剂/基础胰岛素固定剂量复方制剂、口服GLP-1受体激动剂、GLP-1促泌剂等,有望在不久的将来应用于临床实践.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号